|
Patent landscape, scope, and claims: |
Executive summary
US Patent 10,314,788 is directed to an oral opioid monolithic multipart dosage form with an inner expansion layer, an overlying barrier polymer layer (polyacrylate-based), and an overlying drug-containing diffusion layer (quaternary ammonium and related acrylic/methacrylic polymers). The independent claim and most dependents are structured around three measurable performance constructs when the dosage form is divided into more than one piece: (i) exposure metrics at 4 hours (Cmax and/or AUC), (ii) release metrics at 4 hours (drug release rate), and (iii) time-to-peak metrics (Tmax). Claim 39-138 further narrows the drug to a set of five opioids: hydrocodone, morphine, oxycodone, hydromorphone, oxymorphone.
What is not provided in the prompt is the patent’s specification, prosecution history, priority dates, assignee, jurisdictions, figure descriptions, example drug candidates, and the remaining claims not quoted. Without that, the analysis can only parse the textual claim scope you supplied, not determine the exact claim construction outcomes or the full patent family landscape.
What is US Patent 10,314,788 claiming: oral opioid multipart monolithic diffusion-barrier expansion layered compositions?
Core claim architecture (common to Claims 1, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 23, 25, 27, 29, 31, 33, 35, 37)
The repeated structural elements define the infringement “hook”:
1) Dosage form construction: monolithic + divided into multiple pieces
- The composition is an oral pharmaceutical composition.
- The dosage form is a monolithic dosage form.
- The dosage form is divided into more than one piece.
- When at least one piece is administered, performance comparisons are made against an intact dosage form (or a bioequivalent drug composition in comparable/intact form).
2) Three-layer functional stack
Inner expansion layer
- Contains an expansion polymer.
- The layer is “inner” relative to the barrier layer.
Barrier layer
- “Substantially covering” the expansion layer.
- Contains a barrier polymer selected from:
- polyacrylates or copolymers thereof
- mixtures thereof
Diffusion layer
- “Substantially covering” the barrier layer.
- Contains:
- a drug
- a diffusion polymer selected from:
- quarternary (typo as written) ammonium acrylic or methacrylic polymers
- acrylic or methacrylic polymers
- acrylic or methacrylic copolymers
- mixtures thereof
- The drug is substantially homogeneously distributed within the diffusion polymer.
- The drug diffuses from the diffusion layer within the gastrointestinal tract.
Bonding and curing constraints
- Barrier layer is bonded to the diffusion layer.
- Barrier layer and diffusion layer are cured.
3) Diffusion layer thickness constraint
- In the independent claim set as provided, diffusion layer thickness is:
- about 0.1 to 1.0 mm (appears in Claims 1, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20+ up to the portion you quoted until Claim 20 introduces thickness-of-total constraints)
4) Opioid limitation
- Claims tie delivery behavior to an opioid.
- Dependent claims enumerate specific opioids (Claims 39-138).
How do the claims measure “good performance” after dividing the dosage form: Cmax/AUC at 4 hours, Tmax, and release rate?
The claim set uses a consistent comparison template:
- A divided-piece administration is tested.
- A benchmark is used:
- either an intact dosage form of equal drug dosage, or
- an intact dosage form of a bioequivalent drug composition, with equal drug dosage.
- Then the claim imposes “substantially same or lower” / “same or greater” comparisons at specified times, with percentage thresholds in dependents.
A. Exposure at 4 hours (Cmax and/or AUC)
Claim 1 construct
- For divided-piece administration:
- Cmax and/or AUC achieved at 4 hours is substantially the same or lower
- compared to intact dosage form of equal drug dosage
Claim 2 dependent (quantified)
- At least about 20% lower Cmax and/or AUC at 8 hours after administration vs the 4-hour reference in intact form (as written in your text)
Claim 6 construct
- Similar to Claim 1 but benchmark is a bioequivalent intact dosage form
- For divided pieces:
- Cmax and/or AUC at 4 hours is substantially same or lower vs intact bioequivalent
Claim 7 dependent (quantified)
- At least about 20% lower Cmax and/or AUC at 4 hours vs intact bioequivalent
Claim 12 and 25 and 31 variants
- Include divided-piece vs bioequivalent intact constraints
- Dependents (Claims 13, 26, 32) quantify with ≥ 20% lower at 4 hours
B. Release rate at 4 hours
Claim 3 construct
- When divided-piece administration occurs:
- rate of drug released at 4 hours is “substantially the same as” the intact composition of equal dose
Claim 8 construct
- Rate at 4 hours is substantially the same or lower vs intact bioequivalent
Claim 14 construct
- Rate at 4 hours is substantially the same or lower vs intact bioequivalent
Claim 18 construct
- Rate at 4 hours is substantially the same or lower vs intact
Claim 19 and 9 and 15 and 28 and 34 and 37 and 38
Dependents introduce ≥ 20% lower or (in Claim 37) ≥ 10% lower and then ≥ 20% lower in Claim 38, with the same 4-hour release-rate basis.
C. Time-to-peak (Tmax)
Claim 4 construct
- Divided-piece administration:
- Tmax is substantially the same or greater vs intact dosage form of equal dose
Claim 5 dependent
- Tmax at least about 20% greater vs intact
Claim 10/16 variants
- Tmax comparisons include:
- “substantially same or greater” vs intact
- and/or vs intact bioequivalent (Claim 10 is intact; Claim 16 is bioequivalent in your text)
Claims 11 and 17
- Quantify ≥ 20% greater Tmax vs the specified intact reference
What polymer systems and layer ratios are in-scope: expansion polymer + polyacrylate barrier + diffusion polymer?
Barrier polymer limitation is narrower than diffusion polymer
- Barrier polymer is explicitly limited to:
- polyacrylates or copolymers thereof (and mixtures)
That can narrow design-around space if a competitor uses a non-polyacrylate barrier (though literal infringement depends on claim construction and what “selected from the group consisting of” is treated to cover).
Diffusion polymer limitation is broad and overlaps multiple acrylic chemistries
Diffusion polymer is selected from:
- quarternary ammonium acrylic/methacrylic polymers
- acrylic/methacrylic polymers
- acrylic/methacrylic copolymers
- mixtures thereof
This breadth means many acrylic-based diffusion matrices can fall inside scope if they are used as the diffusion layer and the drug is homogeneously distributed.
Diffusion-layer thickness has two different claim “regimes”
- Claims early in the set: diffusion layer thickness about 0.1 to 1.0 mm.
- Later set (Claims 20 onward): diffusion layer thickness comprises:
- about 1 to 30% of total thickness.
This provides two alternative ways to define the physical structure, increasing enforceability against variants that maintain relative thickness rather than absolute thickness.
Which dependent claims narrow the drug to specific opioids (and how many are there)?
From the prompt, the opioid-specific dependent claims are:
- Hydrocodone: Claims 39, 44, 49, 54, 59, 64, 69, 74, 79, 84, 89, 94, 99, 104, 109, 114, 119, 124, 129, 134
- Morphine: Claims 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135
- Oxycodone: Claims 41, 46, 51, 56, 61, 66, 71, 76, 81, 86, 91, 96, 101, 106, 111, 116, 121, 126, 131, 136
- Hydromorphone: Claims 42, 47, 52, 57, 62, 67, 72, 77, 82, 87, 92, 97, 102, 107, 112, 117, 122, 127, 132, 137
- Oxymorphone: Claims 43, 48, 53, 58, 63, 68, 73, 78, 83, 88, 93, 98, 103, 108, 113, 118, 123, 128, 133, 138
That enumeration gives five opioid embodiments across the claim set.
What is the infringement “core”: which claim elements are most likely required in combination?
A typical infringement analysis for a layered composite with multipart division metrics will treat these elements as jointly required for independent claim coverage:
- Monolithic dosage form with more-than-one-piece division
- Inner expansion layer (expansion polymer)
- Barrier layer that substantially covers the expansion layer and uses polyacrylate-based barrier polymers
- Diffusion layer that substantially covers barrier, has:
- the opioid drug
- homogeneously distributed in diffusion polymer
- diffusion polymer chemistry in the listed acrylic/quaternary-ammonium group
- Barrier bonded to diffusion, and both are cured
- Diffusion layer thickness in the claimed numeric range or proportion
- In vivo performance constraints after dividing into pieces:
- Cmax/AUC at 4 hours: same or lower (or at least 20% lower in dependents)
- Tmax: same or greater (or at least 20% greater)
- 4-hour release rate: same or lower with quantified lower thresholds in dependents
How do Claims 1 vs 3 vs 4 vs 6 vs 8 vs 10 vs 12 differ in practical scope?
Claims 1 and 6: exposure suppression at 4 hours
- Claim 1: compared to intact dosage form (equal dose)
- Claim 6: compared to intact dosage form of a bioequivalent drug composition (equal dose)
In enforcement, Claim 6 can be valuable where a challenger’s baseline is framed as bioequivalent rather than the patentee’s own intact formulation.
Claims 3 and 8: release rate constraints
- Claim 3: “substantially the same” release rate at 4 hours vs intact
- Claim 8: “substantially same or lower” vs intact bioequivalent
Claims 4 and 10 and 16 and 23 and 29 and 35 and 36: Tmax control
- Claim 4: Tmax same or greater vs intact
- Claim 10: Tmax same or greater vs intact (in your text)
- Claims later in the set map Tmax vs intact or bioequivalent intact, with quantification in dependents
What design-arounds are suggested by the claim text (without relying on the specification)?
These are claim-text levers, not an assessment of feasibility:
1) Avoid the polyacrylate barrier limitation
If the barrier layer uses a polymer outside “polyacrylates or copolymers thereof,” literal barrier-layer coverage narrows.
2) Avoid the listed diffusion polymer chemistries
If diffusion polymer is not an acrylic/methacrylic polymer or the listed quaternary-ammonium acrylic/methacrylic polymer group, literal diffusion-layer polymer coverage may fail.
3) Change bonding/cure relationship
Removing the claimed “bonded” and “cured” relationship could be a literal avoidance point, depending on how “substantially” and process steps are construed.
4) Eliminate homogenous distribution in diffusion polymer
The claim requires the drug is “substantially homogeneously distributed” in the diffusion polymer.
5) Alter diffusion-layer thickness regime
Avoiding either:
- absolute thickness 0.1 to 1.0 mm, and/or
- relative thickness 1 to 30% of total thickness
can narrow literal capture.
6) Break the multipart division performance requirement
Because the claims repeatedly condition coverage on measured 4-hour and Tmax behavior relative to an intact or bioequivalent intact benchmark, a formulation that produces a different exposure/release profile after division may fall outside these performance-defined limitations.
What does the claim text imply about the intended use-case: opioid “dose splitting” without changing PK too much at 4 hours (or shifting it to later)?
Across claim variants, the performance targets split into two general themes:
- Reduce or cap early exposure at 4 hours (Cmax/AUC or release rate: “same or lower,” with dependents at ≥20% lower).
- Delay or not reduce time-to-peak (Tmax: “same or greater,” with dependents at ≥20% greater).
That suggests the patent is trying to manage PK after division in ways that are measurable on standard PK endpoints.
What is missing to complete a full “patent landscape” (family scope, expiration, freedom-to-operate, and litigation risk)?
The prompt asks for a “scope and claims and patent landscape” for US 10,314,788, but it does not include:
- the filing date / priority date / patent grant date,
- assignee and inventors,
- the full set of claims (only claims 1-138 as provided),
- any family members in other jurisdictions,
- any terminal disclaimers,
- whether there are continuations/divisionals,
- whether the patent is cited in Orange Book listings,
- whether there is ANDA litigation or PTAB activity.
Because those items are essential for any reliable exclusivity timeline, competitor mapping, or litigation/Paragraph IV risk read-through, no further landscape assertions can be made from the information supplied.
Key takeaways
- US 10,314,788 claims a specific multilayer oral opioid multipart monolithic dosage form: expansion layer + polyacrylate barrier bonded to cured diffusion layer containing an acrylic/quaternary-ammonium diffusion polymer with homogeneously distributed drug.
- Coverage is defined not only by structure and polymer chemistry but also by in vivo performance comparisons after splitting into more than one piece, focused on:
- Cmax/AUC at 4 hours (same or lower; dependents use ≥20% lower),
- 4-hour release rate (same or lower; dependents use ≥10% or ≥20% lower depending on the claim),
- Tmax (same or greater; dependents use ≥20% greater).
- Drug scope is narrowed via dependent claims to hydrocodone, morphine, oxycodone, hydromorphone, and oxymorphone.
FAQs
-
Does US 10,314,788 require the dosage form to be split before administration?
Yes. The claim framework requires performance when the monolithic dosage form is divided into more than one piece and at least one piece is administered.
-
Are polyacrylate barriers mandatory for coverage?
Yes. The barrier polymer is limited to polyacrylates or copolymers thereof (and mixtures).
-
Is the diffusion polymer required to be quaternary ammonium acrylic/methacrylic?
No. “Selected from” includes quaternary ammonium acrylic/methacrylic polymers, but it also includes acrylic/methacrylic polymers and acrylic/methacrylic copolymers.
-
Which metric is repeatedly tied to the 4-hour timepoint?
Cmax/AUC at 4 hours and/or drug release rate at 4 hours depending on the claim variant.
-
Which opioids are explicitly covered in the dependent claim set you provided?
Hydrocodone, morphine, oxycodone, hydromorphone, and oxymorphone.
More… ↓
⤷ Start Trial
|
